Recombinant Vaccine Market to Surpass USD 24.10 Bn by 2031

Global Recombinant Vaccine Market is Estimated to Witness High Growth Owing to Increasing Disease Prevalence and Rising Focus on Immunization

The Global Recombinant Vaccine Market is estimated to be valued at USD 11.21 Bn in 2024, exhibiting a CAGR of 11.5% over the forecast period (2024-2031). The recombinant vaccine market is witnessing robust growth owing to factors such as rising prevalence of infectious diseases and increasing focus of various governments on immunization programs. Furthermore, advantages associated with recombinant vaccines such as purity, consistency, and scalability are also driving their adoption.

Market Dynamics:

Increasing prevalence of infectious diseases is one of the major drivers fueling the growth of the global recombinant vaccine market. According to the World Health Organization (WHO), infectious diseases account for approximately 25% of total global deaths every year. Growing incidences of diseases such as hepatitis B, influenza, meningococcal meningitis, and others is increasing the demand for vaccines to provide protection against these infectious agents. Moreover, increasing focus of various governments as well as private manufacturers on vaccination programs aimed at immunizing people is also boosting the recombinant vaccine market. Various government awareness programs have increased understanding among people related to the benefits of vaccines. This has increased vaccination turnout, thereby driving market growth.

Increasing Incidence of Infectious Diseases is Driving the Demand for Recombinant Vaccines

The growing burden of infectious diseases across the globe is a major driver for the recombinant vaccine market. Recombinant vaccines offer significant advantages over traditional vaccines as they can be produced more quickly and easily in larger quantities to meet the rising demand. Diseases such as influenza, hepatitis, HPV, COVID-19, etc. are posing serious public health challenges. According to the World Health Organization (WHO), infectious diseases account for around 26% of global deaths. This high disease prevalence is prompting governments and healthcare organizations to focus on immunization programs using advanced vaccines like recombinant vaccines.

Growing Awareness about Vaccine Preventable Diseases is Fueling the Usage of Recombinant Vaccines

Awareness among the general public and healthcare professionals about the benefits of vaccination against severe infectious illnesses is another key factor propelling the recombinant vaccine market. Various government and non-government organizations are undertaking initiatives to educate people on the importance of vaccination. They are shedding light on how vaccines have substantially reduced mortality and morbidity related to contagious pathogens. This is strengthening the demand for effective and safe recombinant vaccine alternatives. Additionally, the availability of more recombinant vaccines in national immunization programs across regions is positively influencing the market.

High Research and Development Costs can Hamper Market Growth

The research and development process for recombinant vaccines is highly complex and resource-intensive owing to regulatory hurdles. It requires extensive clinical testing to ensure the efficacy and safety of these novel biological entities. This leads to tremendous costs involved in R&D, clinical trials and securing approvals. The estimated cost for developing a new vaccine and obtaining regulatory approval ranges from US$ 200 million to US$ 2.8 billion. Such heavy investments can pose significant challenges, especially for smaller players with limited budgets. This acts as a major restrain for the global recombinant vaccine industry.

 Stringent Regulatory Framework Adds to Compliance Burden

Recombinant vaccines are stringently regulated by agencies like the USFDA and EMA, given the sensitive nature and public health implications. Developers need to present comprehensive documentation at each stage of development to obtain approvals. Even minor changes to an approved recombinant vaccine mandate prior regulatory consent. This regulatory rigor has risen in recent years to ensure maximum safety. However, it increases the compliance burden and prolongs the time-to-market for companies. Navigating the complex regulatory landscape for recombinant vaccines in different regions can also be challenging.

Partnerships and Collaborations Present Promising Opportunities

Collaborations between academic institutions, research organizations and vaccine manufacturers provide a key growth opportunity. By combining complementary expertise and resources, partners can fast-track recombinant vaccine R&D and commercialization. Many players are forming alliances to develop vaccines for underserved disease areas. Similarly, partnerships with government agencies, especially in emerging nations bolster market access and uptake. Outsourcing certain development activities through Contract Development and Manufacturing Organizations (CDMOs) helps optimize costs as well. Overall, strategic collaborations enable participants to overcome bottlenecks and expand their portfolios.

Growing Focus on Therapeutic Vaccines Opens New Avenues

While preventive or prophylactic vaccines dominate currently, therapeutic vaccines targeting conditions like cancer and infectious illnesses are garnering increased attention. Leveraging recombinant DNA technology, researchers are designing therapeutic vaccines focused on strengthening the body's natural defenses to fight diseases. The promising therapeutic applications offer high commercialization potential. As more candidates progress through clinical trials, it can drive significant revenues for market players over the long-run. Governments and charities are also showing enhanced support for funding research in this domain through grants and initiatives.

Link: 

Key Developments:

• In July 2024, BioNet Europe, a subsidiary of BioNet, a vaccine manufacturer, submitted a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its monovalent Recombinant Pertussis Vaccine (RPV). This stand-alone vaccine addresses the increasing cases of whooping cough in Europe and is intended for individuals requiring a pertussis-only booster who are already up-to-date on diphtheria and tetanus immunizations.
• In May 2024, ImmunityBio, a biotechnology company, partnered exclusively with the Serum Institute of India, a leading vaccine manufacturer, to ensure a reliable supply of Bacillus Calmette-Guerin (BCG) vaccines. The agreement covers the production of standard BCG (sBCG) and next-generation recombinant BCG (iBCG) for use with ImmunityBio's ANKTIVA in current and future applications, subject to regulatory approval. This partnership aims to mitigate global BCG shortages impacting bladder cancer patients.
• In November 2023, GC Biopharma, a biopharmaceutical company, applied to the Korean Ministry of Food and Drug Safety (MFDS) for marketing approval of "GC1109," a recombinant anthrax vaccine, developed in collaboration with the Korea Disease Control and Prevention Agency (KDCA). GC1109 demonstrated strong immunogenicity and safety in Phase II trials and aims to combat anthrax, a deadly Class 1 infectious disease, while enhancing preparedness against bioterrorism. If approved, it will be the world's first recombinant anthrax vaccine.
• In December 2020, Sanofi and GSK, healthcare companies, announced a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to enhance immune response in older adults. While Phase 1/2 results showed a robust immune response in adults aged 18-49, the response in older adults was inadequate. An improved antigen formulation demonstrated protection against lung pathology and rapid viral clearance in non-human primates, increasing confidence in its potential for all age groups.

Key Players:

Merck & Co., Inc., Sanofi S.A., Pfizer Inc., GlaxoSmithKline Plc., Johnson & Johnson, Novavax, Inc., AstraZeneca Plc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Emergent BioSolutions Inc., Bharat Biotech, Protein Sciences Corporation, VBI Vaccines Inc., and Inovio Pharmaceuticals, Inc.